Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD

https://doi.org/10.20996/1819-6446-2014-10-3-303-306

Full Text:

Abstract

Adequate primary and secondary prevention of thromboembolic complications is one of the main goals of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use, unfortunately, did not lead to wider and more efficient use of anticoagulation therapy. New oral anticoagulants devoid of drawbacks of warfarin, which prevented its prescription and long-term use, have appeared in the past few years. One of them, the most studied, with the largest list of indications for use, and very attractive, is rivaroxaban.

About the Authors

L. Y. Koroleva
Nizhny Novgorod State Medical Academy
Russian Federation
Minin i Pozharsky pl. 10/1, Nizhny Novgorod, 603950 Russia


I. V. Kolesnichenko
City Cardiology Hospital
Russian Federation
Nesterova ul. 34B, Nizhny Novgorod, 603950 Russia


V. P. Nosov
Nizhny Novgorod State Medical Academy
Russian Federation
Minin i Pozharsky pl. 10/1, Nizhny Novgorod, 603950 Russia


I. I. Gritsenko
City Cardiology Hospital
Russian Federation
Nesterova ul. 34B, Nizhny Novgorod, 603950 Russia


E. S. Timoschenko
City Cardiology Hospital
Russian Federation
Nesterova ul. 34B, Nizhny Novgorod, 603950 Russia


References

1. Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906.

2. Lin H.J., Wolf P.A., Kelly-Hayes V. et al. Stroke severity in atrial fibrillation. The Framingham Study 1996; 27: 1760-4.

3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.

4. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.

5. Sulimov VA, Golitsyn SP, Panchenko EP, et al. National guidelines for the diagnosis and treatment of atrial fibrillation. Russian Journal of Cardiology 2013; (4) suppl 3: 5-100. Russian (Сулимов В.А., Голицын С.П., Панченко Е.П., и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский Кардиологический Журнал 2013; (4) приложение 3: 5-100).

6. Camm A. J., Lip G.Y.H., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 31: 2369-429.

7. Villani G., Piepoli M., Villani P., Capucci A. Anticoagulation in atrial fibrillation: what is certain and what is to come. Eur Heart J 2003; 5 Suppl H: H45-H50.

8. Schwarz U.I., Ritchie M.D., Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358(10):999-1008.

9. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51.

10. Lane D.A., Lip G.Y.H. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation. Circulation 2012: 126: 860-5.

11. Patel M.R., Mahaffey K.W., Garg J., et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.


For citation:


Koroleva L.Y., Kolesnichenko I.V., Nosov V.P., Gritsenko I.I., Timoschenko E.S. PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD. Rational Pharmacotherapy in Cardiology. 2014;10(3):303-306. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-3-303-306

Views: 384


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)